JAMES P ALLISON to Humans
This is a "connection" page, showing publications JAMES P ALLISON has written about Humans.
Connection Strength
0.844
-
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Proc Natl Acad Sci U S A. 2024 Jul 02; 121(27):e2404661121.
Score: 0.019
-
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. J Exp Med. 2024 Apr 01; 221(4).
Score: 0.018
-
Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
Score: 0.017
-
Immune checkpoint therapy: Forging ahead. Sci Transl Med. 2022 11 09; 14(670):eadf2947.
Score: 0.017
-
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 07 05; 218(7).
Score: 0.015
-
The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
Score: 0.015
-
Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020 02; 20(2):75-76.
Score: 0.014
-
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 09; 8(9):1069-1086.
Score: 0.012
-
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018 02; 6(2):189-200.
Score: 0.012
-
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
Score: 0.011
-
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340.
Score: 0.011
-
A conversation with James Allison. J Clin Invest. 2016 Jan; 126(1):3-4.
Score: 0.010
-
Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA. 2015 Sep 15; 314(11):1113-4.
Score: 0.010
-
Checkpoints. Cell. 2015 Sep 10; 162(6):1202-5.
Score: 0.010
-
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunol Res. 2015 Aug; 3(8):849-54.
Score: 0.010
-
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 09; 161(2):205-14.
Score: 0.010
-
The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61.
Score: 0.010
-
Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health. 2014 Jun; 104(6):982-6.
Score: 0.009
-
Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014 Mar; 8(2):117-30.
Score: 0.009
-
FIT testing: an overview. Curr Gastroenterol Rep. 2013 Nov; 15(11):357.
Score: 0.009
-
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013 Jul 01; 210(7):1389-402.
Score: 0.009
-
An open invitation to the cancer immunology community. Cancer Immun. 2012; 12:1.
Score: 0.008
-
Retrospective. Lloyd J. Old (1933-2011). Science. 2012 Jan 06; 335(6064):49.
Score: 0.008
-
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2012 Jun; 217(6):590-2.
Score: 0.008
-
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011 Dec; 106(12):2146-53.
Score: 0.008
-
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011 Oct 24; 11(11):805-12.
Score: 0.008
-
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011 May; 241(1):104-18.
Score: 0.007
-
Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol. 2011 May 01; 186(9):5039-45.
Score: 0.007
-
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010 Oct; 37(5):473-84.
Score: 0.007
-
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010 Aug; 23(8):1104-12.
Score: 0.007
-
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010 Jun; 22(3):326-32.
Score: 0.007
-
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug 03; 206(8):1717-25.
Score: 0.007
-
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev. 2009 May; 229(1):67-87.
Score: 0.006
-
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009 Jul; 157(1):9-19.
Score: 0.006
-
Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008 Sep; 6(9):999-1003.
Score: 0.006
-
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 01; 68(15):6054-8.
Score: 0.006
-
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008 Aug; 224:141-65.
Score: 0.006
-
Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 Feb 01; 68(3):889-92.
Score: 0.006
-
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007 Dec 04; 104(49):19458-63.
Score: 0.006
-
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A. 2007 Nov 06; 104(45):17765-70.
Score: 0.006
-
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5271-9.
Score: 0.006
-
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007 Sep; 12(3):192-9.
Score: 0.006
-
Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol. 2007 Apr; 34(2):165-72.
Score: 0.006
-
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5.
Score: 0.006
-
To be or not to be B7. J Clin Invest. 2006 Oct; 116(10):2590-3.
Score: 0.005
-
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006 Jul 15; 177(2):1052-61.
Score: 0.005
-
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006 Apr; 18(2):206-13.
Score: 0.005
-
Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006; 90:297-339.
Score: 0.005
-
Breaking down the barriers to cancer immunotherapy. Nat Immunol. 2005 Dec; 6(12):1207-10.
Score: 0.005
-
Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol. 2005 Sep; 130(6):809-24.
Score: 0.005
-
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
Score: 0.005
-
Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 2004 Sep; 10(9):887-92.
Score: 0.005
-
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther. 2004; 6(5):208-14.
Score: 0.005
-
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
Score: 0.005
-
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature. 2024 Aug; 632(8023):182-191.
Score: 0.005
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
Score: 0.005
-
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904.
Score: 0.005
-
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? Eur J Cancer. 2024 Feb; 198:113501.
Score: 0.004
-
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res. 2023 11 01; 29(21):4361-4372.
Score: 0.004
-
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10388-92.
Score: 0.004
-
An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles. Gut. 2023 10; 72(10):1904-1918.
Score: 0.004
-
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD? J Fam Pract. 2023 06; 72(5):227-229.
Score: 0.004
-
A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease. Arch Intern Med. 2003 May 26; 163(10):1165-71.
Score: 0.004
-
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
Score: 0.004
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.004
-
Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
Score: 0.004
-
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8.
Score: 0.004
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.004
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.004
-
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
Score: 0.004
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.004
-
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.
Score: 0.004
-
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
Score: 0.004
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.004
-
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
Score: 0.004
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.004
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.004
-
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
Score: 0.004
-
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3556-3566.
Score: 0.004
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.004
-
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2021 03; 11(3):614-625.
Score: 0.004
-
Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
Score: 0.004
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.004
-
Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020 09 17; 5(18).
Score: 0.004
-
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
Score: 0.004
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.003
-
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.
Score: 0.003
-
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020 04 01; 12(537).
Score: 0.003
-
Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
Score: 0.003
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.003
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.003
-
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019 12 16; 7(1):351.
Score: 0.003
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.003
-
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019 10 29; 116(44):22246-22251.
Score: 0.003
-
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
Score: 0.003
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.003
-
Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6501-6510.
Score: 0.003
-
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res. 2019 Sep; 7(9):1390-1395.
Score: 0.003
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
Score: 0.003
-
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:147-164.
Score: 0.003
-
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
Score: 0.003
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.003
-
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
Score: 0.003
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.003
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.003
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.003
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238.
Score: 0.003
-
Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clin Gastroenterol Hepatol. 2018 10; 16(10):1593-1597.e1.
Score: 0.003
-
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105.
Score: 0.003
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.003
-
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018 03 01; 24(5):1011-1018.
Score: 0.003
-
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451.
Score: 0.003
-
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
Score: 0.003
-
The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802.
Score: 0.003
-
Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun; 9(3):396-404.
Score: 0.003
-
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017 04 27; 8:15095.
Score: 0.003
-
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
Score: 0.003
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.003
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.003
-
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
Score: 0.003
-
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105.
Score: 0.003
-
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
Score: 0.003
-
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
Score: 0.003
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.003
-
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016 09 05; 9(1):81.
Score: 0.003
-
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunol Res. 2016 10; 4(10):835-844.
Score: 0.003
-
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
Score: 0.003
-
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res. 2016 Dec 01; 22(23):5729-5737.
Score: 0.003
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.003
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.003
-
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016 07 01; 76(13):3684-9.
Score: 0.003
-
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol Res. 2016 Apr; 4(4):279-88.
Score: 0.003
-
Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct; 7(5):682-6.
Score: 0.003
-
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015 Oct 13; 13(2):412-24.
Score: 0.003
-
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
Score: 0.003
-
Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015 Sep; 21(9):998-1009.
Score: 0.002
-
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
Score: 0.002
-
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995 Jul; 16(7):306-10.
Score: 0.002
-
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
Score: 0.002
-
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015 05 21; 125(21):3335-46.
Score: 0.002
-
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24.
Score: 0.002
-
Translation of cancer immunotherapies. Nat Med. 2004 Nov; 10(11):1153; author reply 1153-4.
Score: 0.002
-
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
Score: 0.002
-
CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994 Jun; 6(3):414-9.
Score: 0.002
-
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16; 25(6):719-34.
Score: 0.002
-
Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014 Apr; 106(4):dju032.
Score: 0.002
-
Immune modulation in cancer with antibodies. Annu Rev Med. 2014; 65:185-202.
Score: 0.002
-
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44.
Score: 0.002
-
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res. 2013 Nov 15; 19(22):6112-25.
Score: 0.002
-
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013 Oct; 1(4):229-34.
Score: 0.002
-
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 1291:1-13.
Score: 0.002
-
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013 Sep; 20(9):3106-11.
Score: 0.002
-
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205.
Score: 0.002
-
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43.
Score: 0.002
-
Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol. 2002 Oct; 14(5):666-72.
Score: 0.002
-
B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol. 2012 Oct 15; 189(8):4165-74.
Score: 0.002
-
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012 Aug; 143(2):382-9.
Score: 0.002
-
Monoclonal antibodies in cancer therapy. Cancer Immun. 2012; 12:14.
Score: 0.002
-
Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 2012; 7(4):e35222.
Score: 0.002
-
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6187-92.
Score: 0.002
-
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 08; 366(10):925-31.
Score: 0.002
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012 Feb 08; 482(7385):400-4.
Score: 0.002
-
Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
Score: 0.002
-
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011 Oct 04; 108(40):16723-8.
Score: 0.002
-
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011 Aug 28; 17(9):1094-100.
Score: 0.002
-
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-?1 cytokine. Immunity. 2011 Jul 22; 35(1):123-34.
Score: 0.002
-
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011 Aug; 60(8):1137-46.
Score: 0.002
-
Introduction: gamma delta T cells--the 'other' T lymphocytes. Semin Immunol. 1991 Mar; 3(2):73-4.
Score: 0.002
-
The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol. 1991; 9:679-705.
Score: 0.002
-
Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. Nucleic Acids Res. 1990 Dec 11; 18(23):7153.
Score: 0.002
-
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71.
Score: 0.002
-
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Apr 01; 116(7):1767-75.
Score: 0.002
-
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun. 2010 Jan 07; 10:1.
Score: 0.002
-
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep 01; 15(17):5323-37.
Score: 0.002
-
Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2373-9.
Score: 0.002
-
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009 Aug; 137(2):502-11.
Score: 0.002
-
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009; 11(7):912-22.
Score: 0.002
-
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20410-5.
Score: 0.002
-
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
Score: 0.002
-
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14.
Score: 0.001
-
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10.
Score: 0.001
-
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 2007 Aug 01; 110(3):954-61.
Score: 0.001
-
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007 Mar; 26(3):311-21.
Score: 0.001
-
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 May 01; 175(9):926-34.
Score: 0.001
-
Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol. 1987; 5:503-40.
Score: 0.001
-
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24(5):442-7.
Score: 0.001
-
The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. 1983. J Immunol. 2006 Mar 01; 176(5):2683-90.
Score: 0.001
-
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005 Feb 15; 174(4):1922-31.
Score: 0.001
-
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16; 22(13-14):1700-8.
Score: 0.001
-
HLA antigens in serum. Methods Enzymol. 1984; 108:614-24.
Score: 0.001
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7.
Score: 0.001
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7.
Score: 0.001
-
Prostate cancer: advances in immunotherapy. BioDrugs. 2003; 17(2):131-8.
Score: 0.001
-
Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. Transplantation. 1978 Dec; 26(6):451-4.
Score: 0.001
-
An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplant Proc. 1977 Dec; 9(4):1691-3.
Score: 0.001
-
Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplant Proc. 1977 Mar; 9(1):601-4.
Score: 0.001
-
Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochem Biophys Res Commun. 1972 Apr 14; 47(1):66-73.
Score: 0.000
-
The gamma T-cell antigen receptor. J Clin Immunol. 1987 Nov; 7(6):429-40.
Score: 0.000
-
The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell. 1983 Nov; 35(1):295-302.
Score: 0.000
-
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol. 1978; 7:239-81.
Score: 0.000
-
Immunogenicity of HLA antigens purified from serum. Transplantation. 1977 Jan; 23(1):7-15.
Score: 0.000
-
[Biological and chemical aspects of histocompatibility antigens in serum]. Haematologica. 1976 Dec; 61(4):397-417.
Score: 0.000
-
HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplant Proc. 1976 Jun; 8(2):173-8.
Score: 0.000